FY2030 EPS Estimates for ProKidney Lowered by HC Wainwright

ProKidney Corp. (NASDAQ:PROK) – HC Wainwright cut their FY2030 earnings per share (EPS) estimates for shares of ProKidney in a report issued on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.08 for the year, down from their previous estimate of $0.10. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.49) per share.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.19 million.

Other analysts also recently issued research reports about the stock. Weiss Ratings raised shares of ProKidney from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 10th. Wall Street Zen cut shares of ProKidney from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

ProKidney Stock Performance

NASDAQ PROK opened at $1.61 on Wednesday. ProKidney has a one year low of $1.45 and a one year high of $3.48. The stock has a 50-day moving average of $1.71 and a 200 day moving average of $1.88. The company has a market capitalization of $486.32 million, a price-to-earnings ratio of -2.93 and a beta of 1.66.

Hedge Funds Weigh In On ProKidney

A number of hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its stake in shares of ProKidney by 14.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,847,749 shares of the company’s stock valued at $3,769,000 after buying an additional 236,056 shares in the last quarter. FNY Investment Advisers LLC raised its holdings in ProKidney by 2,000.0% during the second quarter. FNY Investment Advisers LLC now owns 21,000 shares of the company’s stock valued at $42,000 after acquiring an additional 20,000 shares during the period. Bank of America Corp DE lifted its stake in ProKidney by 6.7% in the 1st quarter. Bank of America Corp DE now owns 753,412 shares of the company’s stock worth $1,349,000 after purchasing an additional 47,268 shares in the last quarter. Amundi lifted its stake in ProKidney by 7.2% in the 1st quarter. Amundi now owns 291,708 shares of the company’s stock worth $522,000 after purchasing an additional 19,466 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in shares of ProKidney during the 1st quarter valued at about $26,000. 51.59% of the stock is currently owned by institutional investors.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.